|
Match
|
Document |
Document Title |
|
|
7595191 |
Isolation and purification of P. falciparum merozoite protein-142 vaccine
In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-1 42 . The method of the present invention produces a highly purified protein which retains...
|
|
|
7575755 |
Immunogenic compositions and uses thereof
The present invention relates generally to a method of eliciting or otherwise inducing an effective immune response to a micro-organism and compositions for use therein. More particularly, the...
|
|
|
7563883 |
Recombinant P. falciparum merozoite protein-142 vaccine
In this application is described the expression and purification of a recombinant Plasmodium falciparum (FVO) MSP-1 42 . The method of the present invention produces a highly purified protein...
|
|
|
7541039 |
Immunization with bacterial ghost-based vaccines
Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain,...
|
|
|
7498037 |
Plasmodium falciparum antigens and their vaccine and diagnostic applications
The invention concerns novel Plasmodium falciparum antigens and their vaccine and diagnostic applications. More particularly, the invention concerns immunogenic polynucleotide and polypeptide...
|
|
|
7488489 |
Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies
Antigenic and immunogenic determinants of Merozoite surface protein 3 (MSP3). Antigenicity and functional assays identified a 68-amino acid conserved domain of MSP3 as a target of biologically...
|
|
|
7476386 |
Mixed lipopeptide micelles for inducing an immune response
The invention concerns mixed micelles or micro-aggregates for inducing an immune response containing at least a first lipopeptide comprising a CTL epitope and at least a first lipid motif; and a...
|
|
|
7462358 |
Antigenic polypeptide SE36 of malaria plasmodium, process for purification thereof, and vaccine and diagnostic agent using the antigen
The present invention provides a polypeptide SE36 derived from the N-terminal domain (47 kd) of SERA (serine-repeat antigen) produced by malaria parasite, Plasonodium falciparum , at the...
|
|
|
7438917 |
Peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes
The present invention relates to an in vitro diagnostic method for malaria in an individual comprising placing a tissue or a biological fluid taken from an individual in contact with a molecule or...
|
|
|
7438916 |
Therapeutic target for protozoal diseases
A novel Fasciclin Related Adhesive Protein (FRAP) from Plasmodium and related parasites is provided as a target for therapeutic intervention in diseases caused by the parasites. FRAP has been...
|
|
|
7431936 |
Proteins involved in cytoadhesion of plasmodium falciparum ring-stage-infected erythrocytes, antibodies which bind to the proteins, and methods for detecting infection, stage of infection and vaccines for protecting against infection
The present invention provides the RSP-1 and RSP-2 proteins which are involved in the cytoadhesion of P. falciparum during ring-stage infection of erythrocytes, antibodies which bind to the...
|
|
|
7404962 |
Combination kit used in the treatment of malaria
A combination kit for the treatment of malaria caused by Plasmodium vivax ( P. vivax ) having individual doses of an anti-malarial agent,...
|
|
|
7306806 |
Recombinant P. falciparum merozoite protein-142 vaccine
In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-1 42 . The method of the present invention produces a highly purified protein which retains...
|
|
|
7285289 |
Nanoparticle vaccines
The present invention relates to nanoparticle vaccines comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed...
|
|
|
7273605 |
Vaccine
The present invention relates to a fowlpox virus genome which has modifications in one or more wild-type FPV genes. The present invention also relates to a viral particle comprising such a genome...
|
|
|
7256281 |
Recombinant P. falciparum merozoite protein-142 vaccine
In this application is described the expression and purification of a recombinant Plasmodium falciparum (FVO) MSP-1 42 . The method of the present invention produces a highly purified protein...
|
|
|
7229627 |
Apparatuses and methods for the production of haematophagous organisms and parasites suitable for vaccine production
Disclosed are apparatuses and methods for the production of attenuated aseptic parasites in hematophagous insects generally, and production of Plasmodium species sporozoites in Anopheles ...
|
|
|
7198791 |
Compositions and methods for the generation of protective immune responses against malaria
The invention presents vaccine formulations comprising highly antigenic epitopes identified within the semi-conserved loop-I of domain III that are capable of eliciting parasite growth inhibitory...
|
|
|
7179615 |
Method of prophylaxis and treatment
The present invention relates generally to a method for the prophylaxis and treatment of parasitic infections in animals and birds. More particularly, the present invention contemplates a method...
|
|
|
7150875 |
Recombinant Plasmodium vivax merozoite protein-1 p42 vaccine
In this application is the expression and purification of a recombinant Plasmodium vivax (SalI) PvMSP-1 p42. The method of the present invention produces a highly purified protein which retains...
|
|
|
7125958 |
Malaria polypeptides
The present invention relates to carbohydrates capable of acting as receptors for malaria antigens present on the surfaces of malaria infected erythrocytes. The receptors according to the invention...
|
|
|
7101556 |
Preparation and usage of plasmodium fusion antigen
The invention provides a fusion protein comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1), the encoding DNA sequence, the vector...
|
|
|
7078507 |
Synthetic genes for malarial proteins and methods of use
Synthetic gene sequences encoding erythrocyte binding protein of a malaria pathogen for the expression of the erythrocyte binding protein. The codon composition of the synthetic gene sequences...
|
|
|
7078043 |
Malaria vaccine
A non-naturally occurring variant of a C-terminal fragment of a Plasmodium merozoite surface protein-1 (MSP-1) wherein said variant has (i) a reduced affinity, compared with a naturally occurring...
|
|
|
7071296 |
Plasmodium falciparum antigens inducing protective antibodies
The present invention relates to immunogenic compositions comprising as an immunogen a long synthetic or recombinant peptide of a merozoite surface protein 3b (MSP-3b) peptide, an MSP-3c peptide...
|
|
|
7067315 |
Identification of anti-protozoal agents
The present invention provides novel assay systems and methods for monitoring cell invasion by protozoal parasites. The present invention further provides methods of using these assays systems to...
|
|
|
7056518 |
Malarial pre-erythrocytic stage polypeptide molecules
Polypeptide molecules containing at least 10 consecutive amino acids of the amino acid sequence shown in FIG. 2, representing the LSA3 antigen, the following peptides being excluded:
...
|
|
|
7029685 |
Plasmodium falciparum AMA-1 protein and uses thereof
In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified...
|
|
|
6958235 |
Recombinant protein containing a C-terminal fragment of plasmodium MSP-1
The invention relates to a recombinant protein fabricated in a baculovirus system, of which the essential constitutive polypeptide sequence is that of a C-terminal fragment of 19 kilodalton (p19)...
|
|
|
6942866 |
Malaria immunogen and vaccine
A chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid protein (HBc) is disclosed that contains an immunogen for inducing the production of antibodies to malarial proteins. An...
|
|
|
6855323 |
Identification of the domain of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) that mediates adhesion to chondroitin sulfate A
The present invention relates to the discovery of a var gene and corresponding protein that modulates adhesion of parasitized red blood cells to chondroitin sulfate A. Novel biological tools,...
|
|
|
6855322 |
Isolation and purification of P. falciparum merozoite protein-142 vaccine
This application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-1 42 . The method of the present invention produces a highly purified protein which retains...
|
|
|
6815183 |
Plasmodium sp. chitinase
The present invention is directed to isolated nucleic acid molecules encoding Plasmodium sp. chitinases . Expression vectors and host cells comprising the nucleic acid molecules are also...
|
|
|
6783765 |
Process for the preparation of a vaccine for the treatment of tuberculosis and other intracellular infections diseases and the vaccine produced by the process
The present invention relates to a process for the preparation of a vaccine against tuberculosis and other intracellular pathogens, this vaccine is targeted against intracellular pathogens, more...
|
|
|
6780415 |
Animal model for infection by an apicomplexan parasite
An animal model for CNS infection by Apicomplexan parasites was produced by inoculating a homologous cell or other type of cell with the merozoite stage of the Apicomplexan parasite and inoculating...
|
|
|
6780417 |
Transmission blocking immunogen from malaria
The present invention relates to transmission blocking vaccines against malaria. Vaccines of the present invention contain a recombinant virus encoding all, or a unique portion, of the 25 kDa...
|
|
|
6669945 |
Universal T-cell epitopes for anti-malarial vaccines
The present invention provides methods and compositions for eliciting protective immunity against malaria. In particular, the invention relates to universal T-cell epitopes that elicit T-cell...
|
|
|
6593463 |
Modified MSP-1 nucleic acid sequences and methods for increasing MRNA levels and protein expression in cell systems
The invention provides modified recombinant nucleic acid sequences (preferably DNA) and methods for increasing the mRNA levels and protein expression of malarial surface protein MSP-1 which is...
|
|
|
6579524 |
Malaria vaccine
The present invention relates to a vaccine against malaria comprising a polypeptide having the amino acid sequence of the C-terminal part of the circumsporozoite protein of a Plasmodium species, in...
|
|
|
6491920 |
Polypeptides and DNA encoding same
Proteins from the merozoite stage of the malaria parasite, fragments and derivatives thereof, DNA coding for the said proteins, and processes for the preparation of the proteins and plasmid and...
|
|
|
6417341 |
Malaria merozoite antigen subunit vaccine
An immunogenic polypeptide for use in inducing an immune response against Plasmodium infection comprises an amino acid sequence corresponding to a non-full length fragment of the apical membrane...
|
|
|
6333406 |
Gene encoding protein antigens of Plasmodium falciparum and uses therefor
A Plasmodium falciparum gene encoding immunogenic SERA protein has been isolated by a) systematically screening a lambda gt11 recombinant DNA expression library with a murine monoclonal antibody...
|
|
|
6316000 |
Cloning and expression of plasmodium falciparum transmission-blocking target antigen, PFS230
Compositions comprising biologically pure Pfs230 and nucleic acids which encode them are provided. The proteins can be used induce transmission blocking immune responses in susceptible hosts.
|
|
|
6214353 |
Malaria recombinant poxvirus vaccine
What is described is a recombinant poxvirus, such as vaccinia virus, containing foreign DNA from Plasmodium Merozoite Surface Antigen 1. What is also described is a vaccine containing the...
|
|
|
6214357 |
Treatment of diabetes
The present invention provides methods for using a killed malaria parasite or an extract thereof in the treatment of non-insulin dependent diabetes mellitus (NIDDM).
|
|
|
6162433 |
Non antibiotic selectable markers for live vaccines
The invention relates to DNA constructs encoding a safe, selectable marker, other than an antibiotic resistance marker, vectors and/or cells including said constructs; and vaccines based on said...
|
|
|
6120770 |
Plasmodium proteins useful for preparing vaccine compositions
The present invention relates to DNA segments encoding MAEBL, an erythrocyte binding protein of a Plasmodium parasite, to substantially pure MAEBL proteins and to recombinantly or synthetically...
|
|
|
6113917 |
Modified polypeptides for enhanced immunogenicity
A recombinant polypeptide comprising a polypeptide which has added thereto a glycoxyl-phosphatidylinositol anchor structure, said polypeptide demonstrating a greater immune response than the...
|
|
|
6100067 |
Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by P. falciparum at the sporozoite stage and in the hepatocytes
The invention relates to a polypeptide characterized in that it contains at least one peptide sequence carrying one or several epitopes characteristic of a protein produced at the sporozoite stage...
|
|
|
6093406 |
Vaccine for induction of immunity to malaria
Vaccines for the induction of immunity to malaria, based on aluminum hydroxide-treated, lipid A- and malarial antigen-containing liposomes, are described. Vaccines of this sort are useful in both...
|